Form 4: Tempest Therapeutics Executive Acquires Stock Options

Tempest Therapeutics Corporate Controller Justin Trojanowski acquired employee stock options, with vesting scheduled to begin in March 2027.

Summary

• Justin Trojanowski, Corporate Controller at Tempest Therapeutics, Inc., acquired employee stock options.
• The options grant the right to buy 22,000 shares of common stock at an exercise price of $1.64 per share.
• The earliest transaction date associated with this filing is March 31, 2026.
• The stock options are set to expire on March 30, 2036.
• Vesting of the options will commence on March 31, 2027, with 25% of the shares vesting on that date.
• The remaining shares will vest in 36 equal monthly installments thereafter, contingent upon continued service.
• Trojanowski beneficially owns 22,000 shares directly through these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive stock option grant and acquisition, typical for compensation structures, rather than a significant event impacting company performance or strategy.

Positives

• Acquisition of stock options by a key executive can signal confidence in the company's future prospects.
• The vesting schedule incentivizes continued service and long-term commitment from the Corporate Controller.

Risks

• The vesting of options is contingent upon the Reporting Person's continued service, implying a risk of forfeiture if employment ceases before vesting milestones are met.
• The exercise price of $1.64 per share means the options will only be profitable if the stock price rises above this level.

Future Outlook

The future outlook for these specific options is tied to the continued service of Justin Trojanowski and the future stock price performance of Tempest Therapeutics, Inc. The vesting schedule indicates a phased release of equity over several years, starting in March 2027.

Industry Context

StockSavvy.ai notes that the issuance and acquisition of stock options to corporate officers is a standard practice in the biotechnology and pharmaceutical sectors, aligning executive compensation with shareholder value and incentivizing long-term performance.

Stakeholder Impact

• Shareholders: The acquisition of options by management can be seen as a positive sign of commitment, but the actual impact on share price depends on the company's future performance.
• Employees: The vesting schedule reinforces the importance of continued employment for executive compensation realization.
• Management: Justin Trojanowski has a direct financial incentive tied to the company's stock performance and his continued tenure.

Next Steps

• Continued service by Justin Trojanowski to meet vesting requirements.
• Monitoring of Tempest Therapeutics' stock price performance relative to the $1.64 exercise price.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Beneficial Ownership, Tempest Therapeutics, TPST, Executive Compensation, Corporate Controller, Vesting Schedule